Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Autoimmune glomerular diseases are characterized by the presence of an autoantigen which may be of glomerular or B cell origin; these autoantigens elicit an autoantibody response by B cells. While autoimmune glomerular diseases are associated with a variety of histopathologic profiles, the fundamental pathophysiology of these kidney diseases is conserved. This mechanistic conservation invites consideration of a basket trial approach to investigate the safety and efficacy of a B-cell modulator in a broad range of glomerular diseases.
Atacicept is a rationally designed biologic protein that binds the two primary cytokines driving B cell activity: B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), with picomolar potency. Atacicept is comprised of the extracellular binding domain of the TACI receptor fused to Fc fragment of IgG. TACI is expressed by B cells and binds circulating BAFF and APRIL; atacicept is a soluble receptor for BAFF and APRIL amenable to chronic subcutaneous self-administration.
In Phase 2 and 3 clinical trials, atacicept has shown compelling evidence of disease modification in immunoglobulin A nephropathy (IgAN). Recently conducted clinical trials in IgAN have generally focused inclusion on participants with high levels of proteinuria and mild-to-moderate impairment in kidney function, criteria which have rendered approximately half of all patients with biopsy-proven IgAN ineligible for enrollment. PIONEER is designed to address this gap, expanding experience with atacicept to a broader population of patients with IgAN. This study also includes participants with nephrotic syndrome of suspected autoimmune origin: primary membranous nephropathy (pMN) and confirmed anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies, and others with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD) with evidence of anti-nephrin autoantibodies.
PIONEER is a global, Phase 2, open-label basket trial designed to assess safety and detect signals of efficacy of atacicept in an expanded cohort of participants with IgAN, as well as anti-PLA2R-associated pMN and anti-nephrin-associated FSGS and MCD. Eligible participants will receive atacicept 150 mg via at-home once-weekly subcutaneous injection for up to 52 weeks.
Approximately 200 participants across 75 sites globally are planned and the trial is open and actively enrolling participants. Key efficacy endpoints will include changes from baseline in urine protein-to-creatinine ratio, estimated glomerular filtration rate, and disease-specific antibody levels.
PIONEER will provide a comprehensive approach to clinical testing of atacicept in autoimmune kidney disease, potentially expanding its applicability in clinical practice.
This abstract was also presented at the ASN Kidney Week 2025 congress.
